Last Updated:
Searching
Create account to add to watchlist!
Create account to add to watchlist!

Biotech Acquisition Co - BIOT

  • Commons

    $9.93

    +0.10%

    BIOT Vol: 53.4K

  • Warrants

    $0.06

    +18.69%

    BIOTW Vol: 302.0

  • Units

    $9.92

    +0.00%

    BIOTU Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 227.9M
Average Volume: 38.6K
52W Range: $8.30 - $10.41
Weekly %: +0.00%
Monthly %: +0.30%
Inst Owners: 77

Info

Target: Searching
Days Since IPO: 615
Unit composition:
Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant
Trust Size: 20000000.0M

🕵Stocktwit Mentions

Academia posted at 2022-09-03T18:57:57Z

$BTC.X $RIOT $BIOT Cant’t wait for regulation to step in. I can’t imagine how much more investable bitcoin would become and how much more liquidity would flow into it if 90% of these other scam coin were forced to shut down.

bigwhalealert posted at 2022-08-29T20:11:13Z

$BIOT BUY/SELL METER Alert Cross 13% +- Technical Analysis https://t8sk.com/BIOT

Last10K posted at 2022-08-22T20:25:00Z

$BIOT just filed a 10-Q Quarterly Report with 6 financial statements and 28 disclosures. Access them all or just read their earnings: https://last10k.com/sec-filings/biot/0001213900-22-050049.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=biot

risenhoover posted at 2022-08-22T20:07:53Z

$BIOT / Biotech Acquisition files form 10-Q https://fintel.io/sf/us/biot?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2022-08-22T20:07:19Z

$BIOT 📜 SEC Form 10-Q filed by Biotech Acquisition Company https://quantisnow.com/i/3317526?utm_source=stocktwits This and other insights appear 45 seconds early at 💪 https://quantisnow.com/feed 💪

Quantisnow posted at 2022-08-15T21:49:28Z

$BIOT 📜 SEC Form NT 10-Q filed by Biotech Acquisition Company https://quantisnow.com/i/3290150?utm_source=stocktwits 45 seconds delayed.

f3d3x9 posted at 2022-08-07T02:08:23Z

$BIOT 💚 👀 5 other watchers!?

ChartMill posted at 2022-08-06T10:12:00Z

$BIOT is currently trading in the upper part of its 52 week range, outperforming the market. https://www.chartmill.com/stock/quote/BIOT/technical-analysis?key=8388b25b-7f53-4811-b353-57f87cf2ee86&utm_source=stocktwits&utm_medium=TA&utm_content=BIOT&utm_campaign=social_tracking

Quantisnow posted at 2022-08-01T12:00:50Z

$BIOT 📰 Blade Therapeutics to Participate in "Drug Development in Pulmonary Medicine" Panel Discussion at 2022 BTIG Biotechnology Conference https://quantisnow.com/i/3212498?utm_source=stocktwits 45 seconds delayed.

Stock_Titan posted at 2022-08-01T12:00:14Z

$BIOT $BIOTU Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference https://www.stocktitan.net/news/BIOT/blade-therapeutics-to-participate-in-drug-development-in-pulmonary-ahy31q0t2yqu.html

Newsfilter posted at 2022-08-01T12:00:10Z

$BIOT Blade Therapeutics to Participate in "Drug Development in Pulmonary Medicine" Panel Discussion at 2022 BTIG Biotechnology Conference https://newsfilter.io/a/b97c2e707e7fc25cc7f24ff20a48338b

Quantisnow posted at 2022-06-17T20:29:33Z

$BIOT 📜 SEC Form RW filed by Biotech Acquisition Company https://quantisnow.com/i/3044109?utm_source=stocktwits 45 seconds delayed.

Last10K posted at 2022-06-17T20:24:35Z

$BIOT just filed with the SEC a Vote of Security Holders and a Financial Exhibit https://last10k.com/sec-filings/biot/0001213900-22-033589.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=biot

Quantisnow posted at 2022-06-17T20:07:24Z

$BIOT 📜 Biotech Acquisition Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits https://quantisnow.com/i/3044104?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-06-17T20:06:45Z

$BIOT Form RW (registration withdrawal request) filed with the SEC https://newsfilter.io/a/50a16ec97032bab7937a458e8b291319

Newsfilter posted at 2022-06-17T20:06:38Z

$BIOT Form 8-K: Submission of Matters to a Vote of Security Holders On June 14, 2022, Biotech Acquisition Company without conducting any business, an extraordinary general meeting of its shareholders... https://newsfilter.io/a/c43856602e730d3d08343b2bb456fb6a

briefingcom posted at 2022-06-13T14:15:15Z

$BIOT and Blade Therapeutics mutually agree to terminate business combination agreement https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20220613081308BIOT&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page

Last10K posted at 2022-06-13T12:46:22Z

$BIOT just filed with the SEC a New Agreement, a Ending Agreement and a Financial Exhibit https://last10k.com/sec-filings/biot/0001213900-22-032368.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=biot

risenhoover posted at 2022-06-13T12:44:06Z

$BIOT / Biotech Acquisition files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2022 (June 10, 2022) BIO https://fintel.io/sf/us/biot?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2022-06-13T12:43:55Z

$BIOT 📜 Biotech Acquisition Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits https://quantisnow.com/i/3019583?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-06-13T12:43:08Z

$BIOT Form 8-K: Entry into a Material Definitive Agreement The information set forth in Item 1.02 below is hereby incorporated by reference into this Item 1.01. Item 1.02 Termination of a Material Def.. https://newsfilter.io/a/710408cd72a49d90c3450a7a28c91738

ChartMill posted at 2022-06-13T12:34:00Z

$BIOT: Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement https://www.chartmill.com/news/BIOT/prnews-2022-6-13-biotech-acquisition-company-and-blade-therapeutics-mutually-agree-to-terminate-business-combination-agreement?utm_source=stocktwits&utm_medium=pressRelease&utm_content=BIOT&utm_campaign=social_tracking

fla posted at 2022-06-13T12:13:38Z

$BIOT [15s. delayed]: Issued Press Release on June 13, 08:06:00: Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Term https://s.flashalert.me/5bbWJ

STCKPRO posted at 2022-06-13T12:13:07Z

$BIOT NEW ARTICLE : Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement https://www.stck.pro/news/BIOT/29329650

Stonkmoon posted at 2022-06-13T12:08:00Z

$BIOT 2022-06-13 08:06 ET Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement https://stonkmoon.com/news/BIOT/d243d349dbe358a710c20d1707dc95b8

Quantisnow posted at 2022-06-13T12:07:20Z

$BIOT 📰 Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement https://quantisnow.com/i/3019319?utm_source=stocktwits 45 seconds delayed.

Stock_Titan posted at 2022-06-13T12:07:04Z

$BIOT Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement https://www.stocktitan.net/news/BIOT/biotech-acquisition-company-and-blade-therapeutics-mutually-agree-to-nlimgcz0flf1.html

Newsfilter posted at 2022-06-13T12:06:35Z

$BIOT Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement https://newsfilter.io/a/d243d349dbe358a710c20d1707dc95b8

shortablestocks posted at 2022-06-07T15:44:19Z

Zero shares available to short currently in $BIOT. https://www.shortablestocks.com/?BIOT

briefingcom posted at 2022-06-03T11:59:52Z

$BIOT and Blade Therapeutics postpone Extraordinary Meeting of Shareholders to approve proposed business combination https://briefing.com/in-depth-analysis/content/article?ArticleId=IN20220603050125BIOT&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page

Management

Our directors, director nominees and officers are as follows: Name Age Position Dr. Michael Shleifer 47 Chief Executive Officer and Chairman of the Board Ivan Jarry 43 Chief Operating Officer Albert F. Hummel 75 Chief Investment Officer and Director Thomas Fratacci 43 Chief Financial Officer and Treasurer Bruno Montanari 46 Director Nominee Paul Bernard 52 Director Nominee Aaron Kim 51 Director Nominee Dr. Michael Shleifer, serves as our Chairman of the Board and Chief Executive Officer. For more than 20 years, Michael has been a leading driver in healthcare innovation. Michael spent four years at L’Oréal (OTCMKTS: LRLCY) before co-founding SPRIM in 2001, of which he is a Managing Partner and which now employs over 500 people in 17 countries, providing consulting and CRO services and stewarding life science clients through the development and delivery of commercially successful health solutions. In 2015, leveraging SPRIM’s novel vantage point in the life sciences industry and the significant deal flow opportunity such positioning affords SPRIM, Michael founded SPRIM Ventures to invest in biotech and digital health solutions with the potential to create new solutions or products in their categories. SPRIM Ventures partnered with Tikehau Capital (EPA: TKO) in 2017 to launch two healthcare and biotechnology focused venture capital funds: TKS1, which launched in 2018 and TKS2, which launched in 2020. To date, the portfolio companies of these funds have grown to a valuation of more than $200 million. Michael received a Masters in Biochemistry from Université Paris Descartes, Paris V, a Masters in Political Science and Economics from Institut D’Etudes Politiques Sciences Po Paris, and a PhD from Pharmacology from Pharmacology from Université Paris Descartes, Paris V. Ivan Jarry serves as our Chief Operating Officer. Ivan is the co-founder and a Managing Partner of SPRIM since June 2001. Additionally, since March 2020 he has served as the Chief Executive Officer of ObvioHealth, Over the course of his career, Ivan has created and grown over 40 companies in the health innovation space ranging from consulting practices to CROs, digital health and biotech ventures. A global entrepreneur having lived and worked in 8 countries, Ivan is fluent in 4 languages. Whether for CROs or advisory SPRIM clients or for SPRIM Ventures, Ivan has a proven track in the healthcare field for identifying market gaps and then leading organizations through the different stages of their development to bring relevant products and services to scale quickly and with operational excellence. Ivan’s expertise lies in seeding and then structuring businesses for rapid growth through platform and process scalability, data integration and effective leadership. He has a proven ability to spearhead complex projects and inject capital investment where needed to amplify competitive advantage, while maximizing operating efficiencies. His passion for curating, developing and motivating collaborative teams to create a high performing and enduring culture has translated to significant growth in both revenue (up to 7 times year-over-year) and valuation (more than $200 million over the past 2 years) for the ventures under his leadership. Ivan received his Masters from EDHEC Business School in France. Albert Hummel serves as our Chief Investment Officer and a member of our Board of Directors. With over 40 years of diverse business and capital markets experience, Al has a history of recognizing valuable business opportunities early on and capitalizing on their intrinsic value, especially in the healthcare market. He has extensive experience in managing research and development projects, as well as managing complex litigation regarding patent rights, contracts and shareholder disputes. Al is currently a Senior Partner of SPRIM, where he has been since 2014. From 2010 to 2013, he was the Chief Executive Officer and President of the formally publicly traded Obagi Medical Products, when the company’s market capitalization was approximately $180 million. As Chief Executive Officer and Director of Cobrek Pharmaceuticals, Inc. from 1998 to December 2012, a private, venture-backed company, Al led the company out of near bankruptcy by instituting a system to locate and exploit special market situations within specific drug sectors. The result was a shorter drug discovery process and a reduction in drug development time. Cobrek was acquired by Perrigo Company PLC in 2012. As Chief Financial Officer of Watson Pharmaceuticals Inc. from October 1991 to December 1994, which became Allergan PLC through multiple acquisitions, Al oversaw the firm’s initial public offering and also developed its operations’ funding strategy and was a member of its board 98 Table of Contents for 28 years. He was CEO, President, co-Founder and Board member of Bradley-Hummel & Company, a firm that provided investment banking services in the healthcare, energy, and financial service industries. Al began his career at Merrill Lynch in New York where he served as a Vice President and provided investment banking services to private, corporate and government (US and foreign) clients. Al received a B.S. from St. Joseph’s University and an MBA from Indiana University. Thomas Fratacci serves as our Chief Financial Officer and Treasurer. Thomas has 20 years of experience in corporate finance and business management in B2B environments. He is responsible for all finance functions within SPRIM and SPRIM Ventures. Thomas began his career at Arthur Andersen and KPMG, and participated in the early years of SPRIM’s development, both in Asia and the US. After his accounting firm experience, Thomas spent 8 years within the WPP Group, successfully leading Kantar AV’s consulting activities in France, Italy and Russia, managing a team of 30 plus and improving all performance key performance indicators while scaling up reporting processes and compliance metrics. Since May 2018, Thomas has been the Group Chief Financial Officer at SPRIM Ventures, developing robust business models for all of the key ventures within SPRIM’s portfolio companies, to support the several financing rounds and exits. Prior to SPRIM, from 2015 to 2017 he was a finance and operations independent consultant at Karner Blue. Thomas received his Masters from EDHEC Business School in France. Bruno Montanari is a director nominee of our company and will commence his service upon the completion of this offering. Bruno brings to our company a wealth of international experience and network in emerging biotech and life sciences. Currently, Bruno is a partner at Seroba Life Sciences, a leading European venture capital fund based in Dublin, where he has been since 2017. Bruno represents Seroba as a member of the board of directors of Storm Therapeutics Ltd., an RNA epigenetics-focused company in Cambridge, England. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology and medical device industries. Prior to joining Seroba in 2017, Bruno was a Partner at Omnes Capital (Paris), in charge of life sciences investments for the venture capital team, where he held board positions in companies such as Argenx (NASDAQ: ARGX), Poxel (EURONEXT: POXEL), and Themis (acquired by Merck & Co.). His previous venture capital experiences were at Atlas Venture (Paris/London), where he sat on the Board of companies such as Cellzome (acquired by GlaxoSmithKline), Newron (SWX: NWRN), Novexel (acquired by AstraZeneca), and at CDP Capital (Paris/Montreal). Bruno also served as an independent board member of iTeos (NASDAQ: ITOS). He started his career in 1999 in London, in the healthcare team of the investment banking divisions of Deutsche Bank and later Merrill Lynch. We believe he is well qualified to serve on our Board due to his extensive industry, investment research, financial market and related experience. Paul Bernard is a director nominee of our company and will commence his service upon the completion of this offering. Paul is a retired Goldman Sachs partner, private investor and non-executive board director. He has lived and worked in Asia for 26 years. During his 19-year career at Goldman from 1990 to 1993 and 1995 to 2011, Paul built Goldman’s market-leading Asia energy and chemicals research franchise and then as Co-Director of Investment Research, built one of the leading investment research teams in Asia. Given his breadth of pan-Asian experience and as a long-serving member of Goldman’s Asia Management Committee, Paul was involved with many of the firm’s strategic growth efforts in Asia. Since retiring from Goldman, Paul has become a successful private investor and valued board member. Paul is a non-executive director of Conrad Petroleum Ltd., Castle European Ltd. and Sandbox Edutainment Holdings Limited. Paul earned a B.A. from the College of the Holy Cross and an MBA from Stanford University. He is a CFA charter holder. We believe he is well qualified to serve on our Board due to his extensive industry, investment research, financial market and related experience. Aaron Kim is a director nominee of our company and will commence his service upon the completion of this offering. Mr. Kim is co-founder and Managing Partner of Valparaiso Capital Partners, an Asia-focused private equity firm regionally based in Singapore. He has been with Valparaiso since 2008. Valparaiso invests in Asian businesses and assets that provide institutional investors with specific participation on a direct investment and non-discretionary basis. Valparaiso co-invests, acts as the sponsor of and represents principal investors for each of its projects. With Board level representation, larger investors have included sovereign wealth funds, public and private university endowments, insurance companies, private equity funds, and multi-family offices. Mr. Kim has been involved in private equity principal investing since 1995 in Asia, leveraging his experience in technology, investment banking, and real estate development, including BSL-2 biology and chemistry laboratory facilities. He has directly managed businesses, mergers and acquisitions, construction developments, information technology infrastructure developments, and exits for over $2 billion in transactions. Prior to Valparaiso, he was Executive Director and head of operations at AXA Japan when it acquired Nippon Group Life in 2000 for $2 billion, where he was responsible for IT and operations, as well as business restructuring activities. From 1997 to 1999, he advised the Brunei 99 Table of Contents Investment & Commercial Bank, which is wholly-owned by the Brunei Investment Agency, the nation’s sovereign wealth fund. From 1990 to 1997, he was Vice President at Citibank in New York, Hong Kong and Singapore in corporate finance, advisory and strategic planning roles. Mr. Kim has a Bachelor’s of Science in Business Administration and Masters in Economics from Boston University. He has working fluency in Japanese and Korean, and he is an American national, originally from Menlo Park, California. We believe he is well qualified to serve on our Board due to his extensive industry, investment research, financial market and related experience. Advisors In addition to our management team and Board of Directors, we have assembled the following accomplished executives and operators to act as our advisors. We expect our advisors to expand the scope of our direct networks and further enrich our sourcing of opportunities. In addition, we believe our advisors’ experience will enable them to provide strategic advice to our eventual target, helping position it for long term success. The company may compensate its advisors for their services as described under “Certain Relationships and Related Party Transactions — Related Party Policy”. Tanguy Serra will serve as an advisor of our company and will commence his service upon the completion of this offering. A Co-Founder of GoodFinch, an environmental, social and governance-focused asset manager, Tanguy brings extensive experience across capital markets, clean energy, and financial technology. As President and Chief Investment Officer of Loanpal, where he has been since January 2018, he quickly helped that company establish market dominance as the top solar project lender in the U.S. Prior to his current roles, Tanguy spent several years in investment banking with Merrill Lynch, Morgan Stanley (London), nearly a decade investing institutional capital at TPG, co-founded Vivint Solar, and served as Chief Operating Officer and President of SolarCity from May 2013 to November 2016 (now a subsidiary of Tesla, Inc.), where he oversaw 10,000 employees, and helped that company achieve a 40% market share. A key member of SolarCity’s a successful management team, Tanguy oversaw origination of approximately 17,000 solar systems per month and tracked performance of hundreds of thousands of systems across geographies. Mr. Serra attended Lycee Montaigne and ESCP Business School. Michael Tillman will serve as an advisor of our company and will commence his service upon the completion of this offering. Mr. Tillman currently serves as a director of AmatarGroup Singapore & Germany, which he founded in March 2020. In this position, Mr. Tillman is responsible for incubator and seed-investments, providing strategic and commercial advice. He has also served as the President and Chief Executive Officer of Vela Holdings PTE. Ltd., Singapore. Vela Holdings PTE Ltd., of which Mr. Tillman was the CEO and co-founder, entered judicial management under Singapore law in February 2015 ending September 2015 when the company resumed normal operations. The judicial management of Vela Holdings arose from unique events and market factors that we do not believe are relevant to Mr. Tillman’s role with us. Mr. Tillman currently serves on the board of Helaxy Inc. Delaware, Tip Biosystems Pte. Ltd. Singapore, and Nanorepro AG. Michael Tillman attended the University of Hamburg. Number, Terms of Office and Appointment of Directors and Officers Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will consist of five members. Each of our directors will hold office for a two-year term. Subject to any other special rights applicable to the shareholders, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the directors present and voting at the meeting of our board of directors or by a majority of the holders of our ordinary shares. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated memorandum and articles of association as it deems appropriate. Our amended and restated memorandum and articles of association provide that our officers may consist of a Chairman, a Chief Executive Officer, a President, a Chief Operating Officer, a Chief Financial Officer, Vice Presidents, a Secretary, Assistant Secretaries, a Treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our board of directors be independent within one year of our initial public offering. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the 100 Table of Contents company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have four “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules prior to completion of this offering. Our board has determined that each of Messrs. Montanari, Bernard and Kim is an independent director under applicable SEC rules and the Nasdaq listing standards. Officer and Director Compensation None of our directors or officers have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on Nasdaq through the earlier of consummation of our initial business combination and our liquidation, we will pay an affiliate of our sponsor a total of $10,000 per month for office space, administrative and support services. Our sponsor, directors, officers, advisors or our or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, directors, officers, advisors or our or any of their respective affiliates. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting, management or other compensation from the combined company. All compensation will be fully disclosed to shareholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our shareholders in connection with a proposed business combination. It is unlikely the amount of such compensation will be known at the time, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our officers after the completion of our initial business combination will be determined by a compensation committee constituted solely by independent directors. We are not party to any agreements with our directors and officers that provide for benefits upon termination of employment. The existence or terms of any such employment or consulting arrangements may influence our management’s motivation in identifying or selecting a target business, and we do not believe that the ability of our management to remain with us after the consummation of our initial business combination should be a determining factor in our decision to proceed with any potential business combination. Committees of the Board of Directors Pursuant to Nasdaq listing rules we will establish three standing committees — an audit committee in compliance with Section 3(a)(58)(A) of the Exchange Act, a compensation committee and a nominating committee, each comprised of independent directors. Under Nasdaq listing rule 5615(b)(1), a company listing in connection with its initial public offering is permitted to phase in its compliance with the independent committee requirements. We do not intend to rely on the phase-in schedules set forth in Nasdaq listing rule 5615(b)(1). Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. The members of our audit committee will be Bruno Montanari, Paul Bernard and Aaron Kim. Paul Bernard will serve as chairman of the audit committee. Each member of the audit committee is financially literate and our board of directors has determined that Mr. Bernard qualifies as an “audit committee financial expert” as defined in applicable SEC rules and has accounting or related financial management expertise. We will adopt an audit committee charter, which will detail the purpose and principal functions of the audit committee, including: • assist board oversight of (1) the integrity of our financial statements, (2) o

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 111.42%
% of Float Held by Institutions 111.42%
Number of Institutions Holding Shares 77

Mutual Fund Holders

Holder Shares Date Reported Value % Out
RiverPark Fds Tr-RiverPark Short Term High Yield Fd 799001 2022-03-30 7878149 3.47
Merger Fund, The 434517 2022-03-30 4284337 1.8900000000000001
Saba Capital Income & Opportunities Fd 109702 2022-04-29 1081661 0.48
RiverNorth Opportunities Fd 47978 2022-04-29 473063 0.21
WCM Alternatives Event Driven Fd 35852 2022-03-30 353500 0.16
Highland Fds I-NexPoint Merger Arbitrage Fund 34781 2022-03-30 342940 0.15
RiverNorth Specialty Finance Corporation 21998 2022-03-30 216900 0.1
JNL Series Trust-JNL/Multi Manager Alternative Fund 20375 2022-03-30 200897 0.09
First Tr Exchange Traded Fd-First Trust Merger Arbitrage Fd 18377 2022-03-30 181197 0.08
JNL Series Trust-JNL/Westchester Capital Event Driven Fund 13147 2022-03-30 129629 0.06

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2022-08-19 Walleye Capital LLC 117,704 $1,170,000 0.0% +43.9% 0.409%
2022-08-16 Jane Street Group LLC 299,920 $2,970,000 0.0% +123.1% 1.043%
2022-08-16 CVI Holdings LLC 292,563 $2,900,000 0.2% +3.2% 1.018%
2022-08-15 Cubist Systematic Strategies LLC 17,811 $180,000 0.0% 0 0.062%
2022-08-15 Citadel Advisors LLC 146,381 $1,450,000 0.0% -83.7% 0.509%
2022-08-15 Castle Creek Arbitrage LLC 50,000 $490,000 0.0% -50.0% 0.174%
2022-08-15 Millennium Management LLC 458,896 $4,540,000 0.0% -23.7% 1.596%
2022-08-12 Hudson Bay Capital Management LP 1,261,609 $12,490,000 0.1% +147.5% 4.388%
2022-08-11 RPO LLC 628,603 $6,220,000 1.6% +270.2% 2.186%
2022-08-11 JPMorgan Chase & Co. 2,016,756 $19,970,000 0.0% 0 7.015%
2022-08-08 Walleye Capital LLC 117,704 $1,170,000 0.0% +43.9% 0.409%
2022-08-05 Landscape Capital Management L.L.C. 38,001 $380,000 0.1% +138.0% 0.132%
2022-08-05 Cowen AND Company LLC 150,000 $1,490,000 0.1% 0 0.522%
2022-08-03 Wolverine Asset Management LLC 251,104 $2,490,000 0.0% +51.3% 0.873%
2022-08-02 Clear Street LLC 100,000 $990,000 0.0% 0 0.348%
2022-05-27 Walleye Capital LLC 81,797 $810,000 0.0% -13.4% 0.285%
2022-05-23 Spartan Fund Management Inc. 24,530 $300,000 0.0% 0 0.085%
2022-05-17 Walleye Capital LLC 81,797 $810,000 0.0% -13.4% 0.285%
2022-05-16 Rivernorth Capital Management LLC 221,674 $2,180,000 0.1% -1.5% 0.771%
2022-05-12 OMERS ADMINISTRATION Corp 247,005 $2,430,000 0.0% +336.2% 0.859%
2022-05-12 Commonwealth of Pennsylvania Public School Empls Retrmt SYS 50,000 $490,000 0.0% 0 0.174%
2022-05-12 Omni Event Management Ltd 844,965 $8,330,000 0.5% +25.4% 2.939%
2022-05-09 Qube Research & Technologies Ltd 179,720 $1,770,000 0.0% 0 0.625%
2022-05-05 BCK Capital Management LP 27,146 $270,000 0.2% 0 0.094%
2022-03-03 Walleye Capital LLC 94,489 $930,000 0.0% 0 0.329%
2022-02-17 Omni Event Management Ltd 673,554 $6,630,000 0.4% 0 2.343%
2022-02-15 DeepCurrents Investment Group LLC 17,730 $170,000 0.0% 0 0.062%
2022-02-14 D. E. Shaw & Co. Inc. 929,085 $9,140,000 0.0% +75.4% 3.232%
2022-02-14 Glazer Capital LLC 110,599 $1,090,000 0.0% 0 0.385%
2022-02-14 Centerbridge Partners L.P. 93,250 $920,000 0.1% -6.8% 0.324%
2022-02-14 Aristeia Capital LLC 1,149,010 $11,310,000 0.2% 0 3.997%
2022-02-11 Bank of Montreal Can 250,000 $2,470,000 0.0% +25.0% 0.870%
2022-02-10 HighTower Advisors LLC 12,072 $120,000 0.0% -9.9% 0.042%
2022-02-09 Wolverine Asset Management LLC 165,653 $1,630,000 0.0% -6.2% 0.576%
2022-02-09 Context Capital Management LLC 194,400 $1,910,000 0.1% 0 0.676%
2022-02-09 Yakira Capital Management Inc. 53,818 $530,000 0.1% 0 0.187%
2022-01-21 Segantii Capital Management Ltd 50,000 $490,000 0.0% 0 0.174%
2021-11-16 Telemetry Investments L.L.C. 40,000 $390,000 0.5% -72.4% 0.139%
2021-11-16 Citadel Advisors LLC 899,881 $8,770,000 0.0% +0.2% 3.130%
2021-11-16 CNH Partners LLC 101,148 $990,000 0.0% +13.8% 0.352%
2021-11-15 Rivernorth Capital Management LLC 224,998 $2,190,000 0.1% 0 0.783%
2021-11-15 Marshall Wace LLP 316,024 $3,080,000 0.0% +216.1% 1.099%
2021-11-15 Capstone Investment Advisors LLC 118,426 $1,150,000 0.0% 0 0.412%
2021-11-15 Dark Forest Capital Management LP 74,328 $720,000 0.3% 0 0.259%
2021-11-15 HighTower Advisors LLC 13,400 $130,000 0.0% 0 0.047%
2021-11-12 PEAK6 Investments LLC 14,093 $140,000 0.0% 0 0.049%
2021-11-12 Arena Capital Advisors LLC CA 300,000 $2,920,000 0.2% +208.4% 1.043%
2021-11-12 Wolverine Asset Management LLC 176,607 $1,720,000 0.0% -4.9% 0.614%
2021-11-09 Picton Mahoney Asset Management 150,000 $1,460,000 0.1% 0 0.522%
2021-11-09 Basso Capital Management L.P. 147,704 $1,440,000 0.2% +2.9% 0.514%
2021-08-17 Citadel Advisors LLC 897,773 $8,680,000 0.0% +0.3% 3.123%
2021-08-16 CNH Partners LLC 88,865 $860,000 0.0% 0 0.309%
2021-08-16 Bank of America Corp DE 166,523 $1,610,000 0.0% +17.7% 0.579%
2021-08-16 LMR Partners LLP 100,000 $970,000 0.0% 0 0.348%
2021-08-16 Fir Tree Capital Management LP 400,000 $3,870,000 0.1% +33.3% 1.391%
2021-08-16 Alyeska Investment Group L.P. 150,000 $1,450,000 0.0% +66.7% 0.522%
2021-08-16 Schonfeld Strategic Advisors LLC 50,000 $480,000 0.0% 0 0.174%
2021-08-16 Telemetry Investments L.L.C. 144,683 $1,400,000 1.9% 0 0.503%
2021-08-16 Linden Advisors LP 678,849 $6,570,000 0.0% 0 2.361%
2021-08-16 Radcliffe Capital Management L.P. 405,900 $3,930,000 0.1% 0 1.412%
2021-08-16 Kamunting Street Capital Management L.P. 317,924 $3,070,000 1.2% 0 1.106%
2021-08-16 Goldman Sachs Group Inc. 235,019 $2,270,000 0.0% +291.0% 0.817%
2021-08-16 Periscope Capital Inc. 760,000 $7,350,000 0.2% +209.6% 2.643%
2021-08-13 Ancora Advisors LLC 10,100 $98,000 0.0% 0 0.035%
2021-08-13 RP Investment Advisors LP 124,469 $1,200,000 0.2% 0 0.433%
2021-08-13 Basso Capital Management L.P. 143,511 $1,390,000 0.2% +86.7% 0.499%
2021-08-13 OLD Mission Capital LLC 10,610 $100,000 0.0% 0 0.037%
2021-08-12 DG Capital Management LLC 450,000 $4,350,000 0.9% 0 1.565%
2021-08-12 Littlejohn & Co. LLC 50,000 $480,000 0.1% 0 0.174%
2021-08-12 Bank of Montreal Can 200,000 $1,940,000 0.0% 0 0.696%
2021-08-11 Arena Capital Advisors LLC CA 97,272 $940,000 0.1% 0 0.338%
2021-08-11 Deutsche Bank AG 250,000 $2,420,000 0.0% 0 0.870%
2021-08-11 Susquehanna International Group LLP 60,459 $590,000 0.0% 0 0.210%
2021-05-18 Castle Creek Arbitrage LLC 100,000 $970,000 0.1% 0 0.348%
2021-05-18 TENOR CAPITAL MANAGEMENT Co. L.P. 280,581 $2,730,000 0.1% 0 0.976%
2021-05-18 Kingstown Capital Management L.P. 300,000 $2,920,000 1.0% 0 1.043%
2021-05-18 Fir Tree Capital Management LP 300,000 $2,910,000 0.1% 0 1.043%
2021-05-18 Berkley W R Corp 49,124 $480,000 0.1% 0 0.171%
2021-05-18 Karpus Management Inc. 25,000 $240,000 0.0% 0 0.087%
2021-05-18 Blackstone Group Inc. 500,000 $4,860,000 0.0% 0 1.739%
2021-05-18 Alyeska Investment Group L.P. 90,000 $880,000 0.0% 0 0.313%
2021-05-18 Centerbridge Partners L.P. 100,000 $970,000 0.1% 0 0.348%
2021-05-18 Citadel Advisors LLC 895,433 $8,690,000 0.0% 0 3.115%
2021-05-18 Jane Street Group LLC 105,707 $1,030,000 0.0% 0 0.368%
2021-05-17 Polar Asset Management Partners Inc. 600,000 $5,830,000 0.1% 0 2.087%
2021-05-17 Goldman Sachs Group Inc. 60,104 $580,000 0.0% 0 0.209%
2021-05-14 Sculptor Capital LP 300,000 $2,920,000 0.0% 0 1.043%
2021-05-14 Whitebox Advisors LLC 125,000 $1,210,000 0.0% 0 0.435%
2021-05-14 Periscope Capital Inc. 245,506 $2,390,000 0.1% 0 0.854%
2021-05-13 Atalaya Capital Management LP 556,875 $5,400,000 1.1% 0 1.937%
2021-05-10 Basso Capital Management L.P. 76,850 $750,000 0.1% 0 0.267%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q QUARTERLY REPORT 2022-08-22 https://www.sec.gov/Archives/edgar/data/1825413/000121390022050049/f10q0622_biotechacq.htm
NT 10-Q NT 10-Q 2022-08-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390022048188/ea164312-nt10q_biotech.htm
RW WITHDRAWAL REQUEST 2022-06-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390022033593/ea161693-rw_biotech.htm
8-K CURRENT REPORT 2022-06-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390022033589/ea161692-8k_biotech.htm
8-K CURRENT REPORT 2022-06-13 https://www.sec.gov/Archives/edgar/data/1825413/000121390022032368/ea161463-8k_biotechacq.htm
425 CURRENT REPORT 2022-06-03 https://www.sec.gov/Archives/edgar/data/1825413/000121390022031005/ea161113-8k425_biotech.htm
8-K CURRENT REPORT 2022-06-03 https://www.sec.gov/Archives/edgar/data/1825413/000121390022031003/ea161113-8k425_biotech.htm
425 CURRENT REPORT 2022-05-31 https://www.sec.gov/Archives/edgar/data/1825413/000121390022030234/ea160797-8k425_biotech.htm
8-K CURRENT REPORT 2022-05-31 https://www.sec.gov/Archives/edgar/data/1825413/000121390022030232/ea160797-8k425_biotech.htm
425 425 2022-05-24 https://www.sec.gov/Archives/edgar/data/1825413/000121390022029170/ea160491-425_biotechacq.htm
424B3 PROSPECTUS 2022-05-24 https://www.sec.gov/Archives/edgar/data/1825413/000121390022029100/f424b30522_biotechacq.htm
425 CURRENT REPORT 2022-05-23 https://www.sec.gov/Archives/edgar/data/1825413/000121390022028953/ea160458-8k425_biotech.htm
8-K CURRENT REPORT 2022-05-23 https://www.sec.gov/Archives/edgar/data/1825413/000121390022028949/ea160458-8k425_biotech.htm
425 FORM 425 2022-05-19 https://www.sec.gov/Archives/edgar/data/1825413/000121390022028309/ea160327-425_biotechacq.htm
425 FORM 425 2022-05-18 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027948/ea160228-425_biotechacq.htm
425 CURRENT REPORT 2022-05-18 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027946/ea160227-8k425_biotech.htm
8-K CURRENT REPORT 2022-05-18 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027942/ea160227-8k425_biotech.htm
425 FORM 425 2022-05-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027646/ea160083-425_biotechacq.htm
425 CURRENT REPORT FILING 2022-05-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027644/ea160174-8k_biotech.htm
8-K CURRENT REPORT FILING 2022-05-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027639/ea160174-8k_biotech.htm
SC 13G 2022-05-16 https://www.sec.gov/Archives/edgar/data/1825413/000093583622000342/biot13g.htm
425 CURRENT REPORT 2022-05-16 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027176/ea160060-8k425_biotech.htm
8-K CURRENT REPORT 2022-05-16 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027161/ea160060-8k425_biotech.htm
10-Q QUARTERLY REPORT 2022-05-16 https://www.sec.gov/Archives/edgar/data/1825413/000121390022027093/f10q0322_biotechacq.htm
425 FORM 425 2022-05-13 https://www.sec.gov/Archives/edgar/data/1825413/000121390022026476/ea159948-425_biotech.htm
425 BAC'S ANNOUNCEMENT OF S-4 EFFECTIVENESS AND CEF 2022-05-10 https://www.sec.gov/Archives/edgar/data/1825413/000121390022024983/ea159627-425_biotechacq.htm
EFFECT 2022-05-09 https://www.sec.gov/Archives/edgar/data/1825413/999999999522001369/xslEFFECTX01/primary_doc.xml
424B3 PROSPECTUS 2022-05-09 https://www.sec.gov/Archives/edgar/data/1825413/000121390022024939/f424b30522_biotechacq.htm
425 CURRENT REPORT 2022-05-09 https://www.sec.gov/Archives/edgar/data/1825413/000121390022024913/ea159623-8k425_biotech.htm
8-K CURRENT REPORT 2022-05-09 https://www.sec.gov/Archives/edgar/data/1825413/000121390022024906/ea159623-8k425_biotech.htm
CORRESP 2022-05-09 https://www.sec.gov/Archives/edgar/data/1825413/000121390022024761/filename1.htm
S-4/A REGISTRATION STATEMENT 2022-05-09 https://www.sec.gov/Archives/edgar/data/1825413/000121390022024633/fs42022a4_biotechacq.htm
CORRESP 2022-05-06 https://www.sec.gov/Archives/edgar/data/1825413/000121390022024634/filename1.htm
UPLOAD 2022-05-06 https://www.sec.gov/Archives/edgar/data/1825413/000000000022004988/filename1.pdf
S-4/A REGISTRATION STATEMENT 2022-05-04 https://www.sec.gov/Archives/edgar/data/1825413/000121390022023789/fs42022a3_biotechacq.htm
UPLOAD 2022-04-22 https://www.sec.gov/Archives/edgar/data/1825413/000000000022004319/filename1.pdf
CORRESP 2022-04-18 https://www.sec.gov/Archives/edgar/data/1825413/000121390022020323/filename1.htm
S-4/A REGISTRATION STATEMENT 2022-04-18 https://www.sec.gov/Archives/edgar/data/1825413/000121390022020222/fs42022a2_biotechacq.htm
425 2022-04-11 https://www.sec.gov/Archives/edgar/data/1825413/000121390022019106/ea158285-425_biotech.htm
8-K CURRENT REPORT 2022-04-11 https://www.sec.gov/Archives/edgar/data/1825413/000121390022019092/ea158285-8k425_biotech.htm
UPLOAD 2022-04-07 https://www.sec.gov/Archives/edgar/data/1825413/000000000022003749/filename1.pdf
425 FORM 425 2022-04-05 https://www.sec.gov/Archives/edgar/data/1825413/000121390022018029/ea158018-425_biotechacq.htm
425 FORM 425 2022-04-04 https://www.sec.gov/Archives/edgar/data/1825413/000121390022017704/ea157938-425_biotechacq.htm
S-4/A REGISTRATION STATEMENT 2022-04-04 https://www.sec.gov/Archives/edgar/data/1825413/000121390022017590/fs42022a1_biotechacq.htm
CORRESP 2022-04-01 https://www.sec.gov/Archives/edgar/data/1825413/000121390022017591/filename1.htm
425 FORM 425 2022-03-31 https://www.sec.gov/Archives/edgar/data/1825413/000121390022016326/ea157648-425_biotechacq.htm
UPLOAD 2022-03-25 https://www.sec.gov/Archives/edgar/data/1825413/000000000022003279/filename1.pdf
425 BAC RULE 425 2022-03-24 https://www.sec.gov/Archives/edgar/data/1825413/000121390022014872/ea157377-425_biotech.htm
425 CURRENT REPORT 2022-03-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390022012622/ea156873-8k425_biotech.htm
8-K CURRENT REPORT 2022-03-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390022012618/ea156873-8k425_biotech.htm
CORRESP 2022-03-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390022012593/filename1.htm
S-4 REGISTRATION STATEMENT 2022-03-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390022012588/fs42022_biotechacq.htm
425 CURRENT REPORT 2022-03-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390022012586/ea156871-8k425_biotech.htm
8-K CURRENT REPORT 2022-03-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390022012579/ea156871-8k425_biotech.htm
10-K ANNUAL REPORT 2022-03-08 https://www.sec.gov/Archives/edgar/data/1825413/000121390022010984/f10k2021_biotechacq.htm
8-K/A AMENDMENT NO. 1 TO FORM 8-K 2022-03-08 https://www.sec.gov/Archives/edgar/data/1825413/000121390022010970/ea156396-8ka1_biotechacq.htm
425 BAC 425 2022-03-07 https://www.sec.gov/Archives/edgar/data/1825413/000121390022010844/ea156516-425_biotech.htm
425 CURRENT REPORT 2022-02-22 https://www.sec.gov/Archives/edgar/data/1825413/000121390022008714/ea156010-8k425_biotech.htm
8-K CURRENT REPORT 2022-02-22 https://www.sec.gov/Archives/edgar/data/1825413/000121390022008710/ea156010-8k425_biotech.htm
SC 13G SCHEDULE 13G 2022-02-14 https://www.sec.gov/Archives/edgar/data/1825413/000121390022007484/ea155227-13gsponsor_biotech.htm
SC 13G/A 2022-02-14 https://www.sec.gov/Archives/edgar/data/1825413/000104106222000080/ACM_13G_Biotech_Amend2.txt
SC 13G SC 13G 2022-02-14 https://www.sec.gov/Archives/edgar/data/1825413/000119312522039781/d299130dsc13g.htm
SC 13G BIOTECH ACQUISITION CO 2022-02-10 https://www.sec.gov/Archives/edgar/data/1825413/000076999322000151/BiotechAcquisitionCo_Final.txt
UPLOAD 2022-01-26 https://www.sec.gov/Archives/edgar/data/1825413/000000000022001084/filename1.pdf
425 CURRENT REPORT 2022-01-12 https://www.sec.gov/Archives/edgar/data/1825413/000121390022001653/ea153875-8k425_biotech.htm
8-K CURRENT REPORT 2022-01-12 https://www.sec.gov/Archives/edgar/data/1825413/000121390022001651/ea153875-8k425_biotech.htm
425 CURRENT REPORT 2022-01-03 https://www.sec.gov/Archives/edgar/data/1825413/000121390022000053/ea153239-8k_biotech.htm
8-K CURRENT REPORT 2022-01-03 https://www.sec.gov/Archives/edgar/data/1825413/000121390022000051/ea153239-8k_biotech.htm
DRS 2021-12-27 https://www.sec.gov/Archives/edgar/data/1825413/000121390021067412/filename1.htm
SC 13G/A 2021-12-14 https://www.sec.gov/Archives/edgar/data/1825413/000089534521001044/ff662023_13ga-biotech.htm
425 FORM 425 2021-11-30 https://www.sec.gov/Archives/edgar/data/1825413/000121390021062557/ea151539-425_biotechacq.htm
10-Q QUARTERLY REPORT 2021-11-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390021060168/f10q0921_biotechacqu.htm
8-K CURRENT REPORT 2021-11-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390021060165/ea150710-8k_biotech.htm
NT 10-Q NOTIFICATION OF LATE FILING 2021-11-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390021059493/ea150711-nt10q_biotech.htm
425 425 2021-11-09 https://www.sec.gov/Archives/edgar/data/1825413/000121390021057787/ea150286-425_biotechacq.htm
425 FORM 425 2021-11-08 https://www.sec.gov/Archives/edgar/data/1825413/000121390021057391/ea150165-425_biotechacq.htm
425 CURRENT REPORT 2021-11-08 https://www.sec.gov/Archives/edgar/data/1825413/000121390021057195/ea148645-8k_biotechacq.htm
8-K CURRENT REPORT 2021-11-08 https://www.sec.gov/Archives/edgar/data/1825413/000121390021057189/ea148645-8k_biotechacq.htm
10-Q QUARTERLY REPORT 2021-08-11 https://www.sec.gov/Archives/edgar/data/1825413/000121390021041642/f10q0621_biotech.htm
10-Q QUARTERLY REPORT 2021-05-24 https://www.sec.gov/Archives/edgar/data/1825413/000121390021028612/f10q0321_biotechacq.htm
8-K CURRENT REPORT 2021-05-24 https://www.sec.gov/Archives/edgar/data/1825413/000121390021028487/ea141535-8k_biotech.htm
NT 10-Q NOTIFICATION OF LATE FILING 2021-05-18 https://www.sec.gov/Archives/edgar/data/1825413/000121390021027430/ea141198-nt10q_biotech.htm
10-K ANNUAL REPORT 2021-03-23 https://www.sec.gov/Archives/edgar/data/1825413/000121390021017267/f10k2020_biotechacquistion.htm
8-K CURRENT REPORT 2021-03-17 https://www.sec.gov/Archives/edgar/data/1825413/000121390021015899/ea137870-8k_biotech.htm
8-K CURRENT REPORT 2021-03-15 https://www.sec.gov/Archives/edgar/data/1825413/000121390021015272/ea137600-8k_biotechacq.htm
10-Q QUARTERLY REPORT 2021-03-11 https://www.sec.gov/Archives/edgar/data/1825413/000121390021014848/f10q0920_biotechacq.htm
SC 13G 2021-02-16 https://www.sec.gov/Archives/edgar/data/1825413/000091957421001692/d8800251_13-g.htm
SC 13G 2021-02-05 https://www.sec.gov/Archives/edgar/data/1825413/000104106221000031/Atalaya-Corbin_Biotech_13G.txt
8-K CURRENT REPORT 2021-02-03 https://www.sec.gov/Archives/edgar/data/1825413/000121390021006543/ea134464-8k_biotechacquis.htm
8-K CURRENT REPORT 2021-01-29 https://www.sec.gov/Archives/edgar/data/1825413/000121390021005456/ea134164-8k_biotechacq.htm
424B4 PROSPECTUS 2021-01-27 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004464/f424b40121_biotechacq.htm
EFFECT 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/999999999521000259/xslEFFECTX01/primary_doc.xml
3 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004130/xslF345X02/ownership.xml
3 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004128/xslF345X02/ownership.xml
3 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004125/xslF345X02/ownership.xml
3 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004123/xslF345X02/ownership.xml
3 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004121/xslF345X02/ownership.xml
3 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004120/xslF345X02/ownership.xml
3 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021004116/xslF345X02/ownership.xml
CERT 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000135445721000098/8A_Cert_BIOT.pdf
8-A12B FOR REGISTRATION OF CERTAIN CLASSES 2021-01-25 https://www.sec.gov/Archives/edgar/data/1825413/000121390021003942/ea133831-8a12b_biotech.htm
CORRESP 2021-01-22 https://www.sec.gov/Archives/edgar/data/1825413/000121390021003797/filename1.htm
CORRESP 2021-01-22 https://www.sec.gov/Archives/edgar/data/1825413/000121390021003794/filename1.htm
S-1/A 2021-01-20 https://www.sec.gov/Archives/edgar/data/1825413/000121390021002943/fs12020a1_biotechacq.htm
CORRESP 2021-01-19 https://www.sec.gov/Archives/edgar/data/1825413/000121390021002946/filename1.htm
UPLOAD 2021-01-14 https://www.sec.gov/Archives/edgar/data/1825413/000000000021000471/filename1.pdf
S-1/A AMENDMENT NO. 1 TO FORM S-1 2021-01-12 https://www.sec.gov/Archives/edgar/data/1825413/000121390021001546/ea133029-s1a1_biotechacq.htm
S-1 REGISTRATION STATEMENT 2020-12-31 https://www.sec.gov/Archives/edgar/data/1825413/000121390020045543/fs12020_biotechacq.htm
CORRESP 2020-12-30 https://www.sec.gov/Archives/edgar/data/1825413/000121390020045545/filename1.htm
UPLOAD 2020-11-18 https://www.sec.gov/Archives/edgar/data/1825413/000000000020011039/filename1.pdf
DRSLTR 2020-11-13 https://www.sec.gov/Archives/edgar/data/1825413/000121390020036972/filename1.htm
DRS/A 2020-11-13 https://www.sec.gov/Archives/edgar/data/1825413/000121390020036969/filename1.htm
UPLOAD 2020-10-16 https://www.sec.gov/Archives/edgar/data/1825413/000000000020009824/filename1.pdf
DRS 2020-09-21 https://www.sec.gov/Archives/edgar/data/1825413/000121390020027483/filename1.htm